Dr. Kathy Jenkins directs the Cardiology Clinical Research and Regulatory Group, which conducts studies examining variation in outcomes for patients with congenital heart disease and evaluating new therapeutic modalities to treat congenital heart defects. Dr. Jenkins has identified myofibroblastic proliferation as the putative cause for progressive pulmonary vein stenosis, and is running a novel treatment protocol with chemotherapeutic agents. In addition, she is currently seeking FDA approval for a feasibility study investigating the use of a contrast agent during magnetic resonance lymphangiography to evaluate lymphatic disease in high-risk patients. Dr. Jenkins works closely with multi-disciplinary investigators, interventional cardiologists, device manufacturers, pharmaceutical companies, industry sponsors, and regulatory bodies such as the FDA to ensure that clinical trials are conducted properly.
Dr. Jenkins and Dr. Kimberlee Gauvreau developed the Risk Adjustment in Congenital Heart Surgery (RACHS-1) method to allow for meaningful comparisons of congenital heart surgery outcomes, and have extended this work in measure development to other cardiac and non-cardiac conditions. Dr. Jenkins also serves as the primary research mentor for junior faculty, and provides guidance about research study design and implementation to students, fellows, and faculty.